|
1
|
Wang X, Jiang F, Mu J, Ye X, Si L, Ning S,
Li Z and Li Y: Arsenic trioxide attenuates the invasion potential
of human liver cancer cells through the demethylation-activated
microRNA-491. Toxicol Lett. 227:75–83. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen XP, Qiu FZ, Wu ZD, Zhang ZW, Huang
ZY, Chen YF, Zhang BX, He SQ and Zhang WG: Effects of location and
extension of portal vein tumor thrombus on long-term outcomes of
surgical treatment for hepatocellular carcinoma. Ann Surg Oncol.
13:940–946. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sicklick JK, Li YX, Jayaraman A, Kannangai
R, Qi Y, Vivekanandan P, Ludlow JW, Owzar K, Chen W, Torbenson MS
and Diehl AM: Dysregulation of the Hedgehog pathway in human
hepatocarcinogenesis. Carcinogenesis. 27:748–757. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Che L, Yuan YH, Jia J and Ren J:
Activation of sonic hedgehog signaling pathway is an independent
potential prognosis predictor in human hepatocellular carcinoma
patients. Chin J Cancer Res. 24:323–331. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen JS, Huang XH, Wang Q, Huang JQ, Zhang
LJ, Chen XL, Lei J and Cheng ZX: Sonic hedgehog signaling pathway
induces cell migration and invasion through focal adhesion
kinase/AKT signaling-mediated activation of matrix
metalloproteinase (MMP)-2 and MMP-9 in liver cancer.
Carcinogenesis. 34:10–19. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lu JT, Zhao WD, He W and Wei W: Hedgehog
signaling pathway mediates invasion and metastasis of
hepatocellular carcinoma via ERK pathway. Acta Pharmacol Sin.
33:691–700. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
LoRusso PM, Rudin CM, Reddy JC, Tibes R,
Weiss GJ, Borad MJ, Hann CL, Brahmer JR, Chang I, Darbonne WC, et
al: Phase I trial of hedgehog pathway inhibitor vismodegib
(GDC-0449) in patients with refractory, locally advanced or
metastatic solid tumors. Clin Cancer Res. 17:2502–2511. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen JS, Li HS, Huang JQ, Zhang LJ, Chen
XL, Wang Q, Lei J, Feng JT, Liu Q and Huang XH: Down-regulation of
Gli-1 inhibits hepatocellular carcinoma cell migration and
invasion. Mol Cell Biochem. 393:283–291. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jeng KS, Sheen IS, Jeng WJ, Yu MC, Tsai
HH, Chang FY and Su JC: Blockade of the sonic hedgehog pathway
effectively inhibits the growth of hepatoma in mice: An in vivo
study. Oncol Lett. 4:1158–1162. 2012.PubMed/NCBI
|
|
10
|
Yauch RL, Dijkgraaf GJ, Alicke B, Januario
T, Ahn CP, Holcomb T, Pujara K, Stinson J, Callahan CA, Tang T, et
al: Smoothened mutation confers resistance to a Hedgehog pathway
inhibitor in medulloblastoma. Science. 326:572–574. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Buonamici S, Williams J, Morrissey M, Wang
A, Guo R, Vattay A, Hsiao K, Yuan J, Green J, Ospina B, et al:
Interfering with resistance to smoothened antagonists by inhibition
of the PI3K pathway in medulloblastoma. Sci Transl Med. 2:51–70.
2010. View Article : Google Scholar
|
|
12
|
Tang Y, Gholamin S, Schubert S, Willardson
MI, Lee A, Bandopadhayay P, Bergthold G, Masoud S, Nguyen B, Vue N,
et al: Epigenetic targeting of Hedgehog pathway transcriptional
output through BET bromodomain inhibition. Nat Med. 20:732–740.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang Z, He N and Zhou Q: Brd4 recruits
P-TEFb to chromosomes at late mitosis to promote G1 gene expression
and cell cycle progression. Mol Cell Biol. 28:967–976. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Segura MF, FontanalsCirera B, GazielSovran
A, Guijarro MV, Hanniford D, Zhang G, González-Gomez P, Morante M,
Jubierre L, Zhang W, et al: BRD4 sustains melanoma proliferation
and represents a new target for epigenetic therapy. Cancer Res.
73:6264–6276. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Puissant A, Frumm SM, Alexe G, Bassil CF,
Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P,
et al: Targeting MYCN in neuroblastoma by BET bromodomain
inhibition. Cancer Discov. 3:308–323. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cheng Z, Gong Y, Ma Y, Lu K, Lu X, Pierce
LA, Thompson RC, Muller S, Knapp S and Wang J: Inhibition of BET
bromodomain targets genetically diverse glioblastoma. Clin Cancer
Res. 19:1748–1759. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Patel AJ, Liao CP, Chen Z, Liu C, Wang Y
and Le LQ: BET bromodomain inhibition triggers apoptosis of
NF1-associated malignant peripheral nerve sheath tumors through Bim
induction. Cell Rep. 6:81–92. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ott CJ, Kopp N, Bird L, Paranal RM, Qi J,
Bowman T, Rodig SJ, Kung AL, Bradner JE and Weinstock DM: BET
bromodomain inhibition targets both c-Myc and IL7R in high-risk
acute lymphoblastic leukemia. Blood. 120:2843–2852. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lockwood WW, Zejnullahu K, Bradner JE and
Varmus H: Sensitivity of human lung adenocarcinoma cell lines to
targeted inhibition of BET epigenetic signaling proteins. Proc Natl
Acad Sci USA. 109:19408–19413. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lamoureux F, Baud'huin M, Rodriguez
Calleja L, Jacques C, Berreur M, Rédini F, Lecanda F, Bradner JE,
Heymann D and Ory B: Selective inhibition of BET bromodomain
epigenetic signalling interferes with the bone-associated tumour
vicious cycle. Nat Commun. 5:35112014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vihinen P, Alaaho R and Kähäri VM: Matrix
metalloproteinases as therapeutic targets in cancer. Curr Cancer
Drug Targets. 5:203–220. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Freije JM, Balbín M, Pendás AM, Sánchez
LM, Puente XS and López-Otín C: Matrix metalloproteinases and tumor
progression. Adv Exp Med Biol. 532:91–107. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gao J, Ding F, Liu Q and Yao Y: Knockdown
of MACC1 expression suppressed hepatocellular carcinoma cell
migration and invasion and inhibited expression of MMP2 and MMP9.
Mol Cell Biochem. 376:21–32. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu Q, Liu X, Zheng X, Yao Y, Wang M and
Liu Q: The transcriptional activity of Gli1 is negatively regulated
by AMPK through Hedgehog partial agonism in hepatocellular
carcinoma. Int J Mol Med. 34:733–741. 2014.PubMed/NCBI
|
|
25
|
Zheng X, Zeng W, Gai X, Xu Q, Li C, Liang
Z, Tuo H and Liu Q: Role of the Hedgehog pathway in hepatocellular
carcinoma (review). Oncol Rep. 30:2020–2026. 2013.PubMed/NCBI
|
|
26
|
Pinter M, Sieghart W, Schmid M, Dauser B,
Prager G, Dienes HP, Trauner M and Peck-Radosavljevic M: Hedgehog
inhibition reduces angiogenesis by downregulation of tumoral VEGF-A
expression in hepatocellular carcinoma. United European
Gastroenterol J. 1:265–275. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang Y, Han C, Lu L, Magliato S and Wu T:
Hedgehog signaling pathway regulates autophagy in human
hepatocellular carcinoma cells. Hepatology. 58:995–1010. 2013.
View Article : Google Scholar : PubMed/NCBI
|
